Melphalan remains the most widely used agent in preparative regimens for hematopoietic
stem cell transplantation (SCT). From its initial discovery more than 50 years ago, it has …

Haploidentical SCT (haplo-SCT) has been considered a therapeutic option in patients with
acquired severe aplastic anemia (SAA) failing at least one course of immune suppressive …

This pilot study tested feasibility of natural killer cell purification and infusion (NK-DLI) in
patients after haploidentical hematopoietic stem cell transplantation (HSCT). The aim was to …

Patients with refractory severe aplastic anemia (SAA) who lack a matched sibling or
unrelated donor need new therapeutic approaches. Hematopoietic SCT (HSCT) using …

We evaluated the outcome of children and adolescents with acquired severe aplastic
anemia (SAA) who received haploidentical hematopoietic stem cell transplantation (HHCT) …

We retrospectively compared the incidence of virus infections and outcome in the context of
immune reconstitution in two different HLA-haploidentical transplantation (haplo-HSCT) …

Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for severe aplastic
anemia (SAA) is mainly limited by the high incidence of graft failure and GvHD …

Allogeneic bone marrow transplantation relies on immunosuppression, which controls graft-
versus-host disease (GVHD) and allows engraftment at the expense of diminished graft …

Studies of haploidentical hematopoietic stem cell transplantation (HSCT) have identified
threshold doses of T cells below which severe GVHD is usually absent. However, little is …

Haploidentical SCT (HaploSCT) has been most commonly performed using a myeloablative,
TBI-based preparative regimen; however, the toxicity with this approach remains very high …